viewAusCann Group Holdings Ltd
The new collaboration will develop research and technical capabilities.
’s () strategic partner Canopy Growth Corporation has entered into a research collaboration to develop research and technical capabilities in the production of medical cannabis.
The collaboration with the Victorian State Government will see Canopy work to develop new and novel approaches to cannabis cultivation and manufacturing.
READ: Auscann Group’s shares surge following green light for medicinal cannabis export
AusCann reached a new high of $1.86 on 9 January 2018 and today were up to $1.82, an increase of 128% since the start of 2018.
Mark Zekulin, president of Canopy Growth, said: “We look forward to our work with the Victorian Government in the coming months and years.
“Along with our partnership with AusCann, we are excited to be working in Australia as it establishes itself as a leading cannabis jurisdiction.
“This work in Australia will be of benefit to Australian cannabis patients and our partner AusCann, given our proven ability to transport live genetics right across the world and our closer proximity.”
READ: AusCann Group Holdings advances medical cannabis supply chain strategy
The collaboration is aimed at creating a faster pathway towards commercial production of cannabinoid medicines for Australian patients.
ASX:AC8
Market: ASX
Market Cap: $93.53 m
Follow
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of AusCann Group Holdings Ltd named herein, including the promotion by the Company of AusCann Group Holdings Ltd in any Content on the Site, the...
FOR OUR FULL DISCLAIMER CLICK HEREMost read
Auscann targeting pain management with Australian cannabinoid products
Elaine Darby, managing director of Auscann Group Holdings Ltd (ASX:AC8), spoke to Proactive Investors at the ASX Small and Mid-Cap Conference in Sydney. Auscann is continuing to make steady progress towards releasing its first medicinal cannabis products during the financial year 2019....
on 09/05/2018
2 min read
Prev article
2 min read
